Novocure is focused on generating clinical data that supports the use of Tumor Treating Fields (TTFields) therapy to improve treatment outcomes and quality of life for patients with multiple solid cell tumor types. We post clinical trial protocol information for all of our studies on the National Institutes of Health (NIH) website at www.clinicaltrials.gov.
The following company-sponsored trials are currently open and recruiting:
Indication: Newly diagnosed glioblastoma multiforme
Protocol number: NCT00916409
Indication: Pancreatic adenocarcinoma
Protocol number: NCT01971281
Indication: Ovarian carcinoma
Protocol number: NCT02244502
Indication: 1-5 brain metastasis from non-small cell lung cancer
Protocol number: NCT01755624
Additional investigator-sponsored trials are also ongoing. For the most up-to-date clinical trial information, including protocol details, please refer to www.clinicaltrials.gov.
This information is for medical and scientific/educational purposes only. TTFields are experimental for the treatment of patients with new diagnosed glioblastoma, brain metastases, advanced pancreatic adenocarcinoma and ovarian carcinoma and has not been approved by the US Food and Drug Administration for commercial use in these indications. Limited by Federal law to investigational use only.